LATEST TRIALS

  • Solide Tumores
    An open-level, multicentre, dose-escalation, phase I study with an expansion phase, to evaluate safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic
  • Lymphoma
    Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal AntibodyKW-0761(mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma (PTCL)
  • Lymphoma
    Chemo-immunotherapy with early central nervous system (CNS) prophylaxis

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen